FDA Clears Adjunctive AI for Non-Contrast CT of Brain Injuries and Hemorrhages
RapidAI’s Rapid Hyperdensity tool reportedly allows quicker assessment of hyperdense tissue in the brain via non-contrast computed tomography (CT) scans.
RapidAI has received FDA 510(k) clearance for Rapid Hyperdensity, an artificial intelligence (AI)-enabled tool that may allow for more timely assessment of traumatic brain injuries and hemorrhages.
Rapid Hyperdensity’s AI-powered review of non-contrast computed tomography (CT) enables radiologists to quickly determine the extent of hyperdense tissue volume associated with acute neurological conditions such as intracerebral hemorrhage (ICH), according to RapidAI.
Alejandro M. Spiotta, M.D., said the automated detection of intracranial hyperdense tissue volume with Rapid Hyperdensity is a significant advance in facilitating timely triage and ongoing assessment of patients with ICH.
“Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient,” noted Dr. Spiotta, the director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention.”
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
